<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: Patients with multiple colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> may carry germline mutations in the APC or MUTYH genes </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVES: To determine the prevalence of pathogenic APC and MUTYH mutations in patients with multiple colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> who had undergone genetic testing and to compare the prevalence and clinical characteristics of APC and MUTYH mutation carriers </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study conducted among 8676 individuals who had undergone full gene sequencing and large rearrangement analysis of the APC gene and targeted sequence analysis for the 2 most common MUTYH mutations (Y179C and G396D) between 2004 and 2011 </plain></SENT>
<SENT sid="3" pm="."><plain>Individuals with either mutation underwent full MUTYH gene sequencing </plain></SENT>
<SENT sid="4" pm="."><plain>APC and MUTYH mutation prevalence was evaluated by <z:mpath ids='MPATH_491'>polyp</z:mpath> burden; the clinical characteristics associated with a pathogenic mutation were evaluated using logistic regression analyses </plain></SENT>
<SENT sid="5" pm="."><plain>MAIN OUTCOME MEASURE: Prevalence of pathogenic mutations in APC and MUTYH genes </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath> were reported in 7225 individuals; 1457 with classic <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> (â‰¥100 <z:mpath ids='MPATH_270'>adenomas</z:mpath>) and 3253 with attenuated <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> (20-99 <z:mpath ids='MPATH_270'>adenomas</z:mpath>) </plain></SENT>
<SENT sid="7" pm="."><plain>The prevalence of pathogenic APC and biallelic MUTYH mutations was 95 of 119 (80% [95% CI, 71%-87%]) and 2 of 119 (2% [95% CI, 0.2%-6%]), respectively, among individuals with 1000 or more <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 756 of 1338 (56% [95% CI, 54%-59%]) and 94 of 1338 (7% [95% CI, 6%-8%]) among those with 100 to 999 <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 326 of 3253 (10% [95% CI, 9%-11%]) and 233 of 3253 (7% [95% CI, 6%-8%]) among those with 20 to 99 <z:mpath ids='MPATH_270'>adenomas</z:mpath>, and 50 of 970 (5% [95% CI, 4%-7%]) and 37 of 970 (4% [95% CI, 3%-5%]) among those with 10 to 19 <z:mpath ids='MPATH_270'>adenomas</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain><z:mpath ids='MPATH_270'>Adenoma</z:mpath> count was strongly associated with a pathogenic mutation in multivariable analyses </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Among patients with multiple colorectal <z:mpath ids='MPATH_270'>adenomas</z:mpath>, pathogenic APC and MUTYH mutation prevalence varied considerably by <z:mpath ids='MPATH_270'>adenoma</z:mpath> count, including within those with a classic <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> phenotype </plain></SENT>
<SENT sid="10" pm="."><plain>APC mutations predominated in patients with classic <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e>, whereas prevalence of APC and MUTYH mutations was similar in attenuated <z:e sem="disease" ids="C0334108" disease_type="Neoplastic Process" abbrv="">polyposis</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>These findings require external validation </plain></SENT>
</text></document>